| CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE |
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendments to specific patent claims A hearing on infringement of EP 4 023 755 B1 which will also include EP 3 708 668 B1, the validity of which was confirmed in amended form in March 2025, is scheduled for July 1, 2025, before the Regional Court Düsseldorf, Germany TUBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / May 15, 2025 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 4 023 755 B1 subject to amendments to specify the scope of protection. |
accessnewswire.com |
2025-05-15 20:45:00 |
Czytaj oryginał (ang.) |
| CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript |
CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih - Vice President, Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendila - Chief Scientific Officer Axel Sven Malkomes - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America Ryan McElroy - Leerink Partners Roger Song - Jefferies Jasmine Fels - UBS Roy Buchanan - Citizens JMP Jonathan Miller - Evercore ISI Chiara Montironi - Kempen Operator Greetings. |
seekingalpha.com |
2025-04-10 16:59:42 |
Czytaj oryginał (ang.) |
| CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update |
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025 Filed IND and CTA submissions for Phase 1 study with proprietary off-the-shelf program in squamous non-small cell lung cancer (sqNSCLC) Received FDA clearance to proceed with sqNSCLC Phase 1 study; expected to start in H2 2025 Invoiced €10 million milestone payment following initiation of Phase 1 of the combined Phase 1/2 study of a seasonal influenza/COVID-19 combination vaccine; program fully licensed to GSK Received positive validity decision for patent EP 3 708 668 B1 in amended form from European Patent Office (EPO) in inter partes proceedings against BioNTech SE Jury trial in U.S. litigation postponed to September 8, 2025, by the District Court of the Eastern District of Virginia Cash and cash equivalents position of €481.7 million as of December 31, 2024; reaffirming expected cash runway into 2028 CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m. |
accessnewswire.com |
2025-04-10 11:30:00 |
Czytaj oryginał (ang.) |
| CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 |
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2024 on Thursday, April 10, 2025. |
accessnewswire.com |
2025-04-08 11:25:00 |
Czytaj oryginał (ang.) |
| CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer |
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes novel tumor epitopes identified through proprietary whole genome-based discovery platform Enhanced Combination Therapy: CVHNLC to be tested in combination with pembrolizumab, aiming to amplify targeted anti-tumor immune responses Clinical Progress: Patient treatment anticipated to start in the second half of 2025 Pipeline Advancement: IND clearance highlights CureVac's continued oncology pipeline growth, with more candidates planned to enter the clinic in 2026 TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / April 7, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC in patients with squamous non-small cell lung cancer (sqNSCLC). |
accessnewswire.com |
2025-04-07 11:15:00 |
Czytaj oryginał (ang.) |
| European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps |
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. |
benzinga.com |
2025-03-28 10:58:22 |
Czytaj oryginał (ang.) |
| European Patent Office declares CureVac mRNA patent valid |
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday. |
reuters.com |
2025-03-27 20:22:39 |
Czytaj oryginał (ang.) |
| CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE |
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court Düsseldorf Confirming validity of patent in its amended form marks major milestone in broader patent litigation in Germany, recognizing CureVac's pioneering mRNA innovation TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / March 27, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. |
accessnewswire.com |
2025-03-27 18:30:00 |
Czytaj oryginał (ang.) |
| CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators |
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its recognition as a Top 100 Global Innovator in the Innovation Momentum 2025 report by LexisNexis®. |
accessnewswire.com |
2025-02-18 09:15:00 |
Czytaj oryginał (ang.) |
| CureVac: Latest GBM Data Bodes Well For Next Program Check Point |
CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025. |
seekingalpha.com |
2025-01-08 18:55:42 |
Czytaj oryginał (ang.) |
| 2 Small-Cap Stocks Set to Shine in a Bull Market |
Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities. |
marketbeat.com |
2024-12-16 09:30:01 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in CureVac (CVAC) Stock? |
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately. |
zacks.com |
2024-11-20 14:21:08 |
Czytaj oryginał (ang.) |
| CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript |
CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Axel Malkomes - Chief Financial Officer Myriam Mendila - Chief Development Officer Rudiger Wolff - Senior Vice President of Finance Conference Call Participants Charlie Yang - Bank of America Merrill Lynch CJ Yeh - Leerink Partners Roy Buchanan - Citizens JMP Operator Greetings and welcome to the CureVac Financial Results and Business Update for the Third Quarter and First Nine Months of 2024 Conference Call. |
seekingalpha.com |
2024-11-12 17:08:31 |
Czytaj oryginał (ang.) |
| CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update |
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025 New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment Corporate redesign on track with 30% workforce reduction, expected to yield significant annual cost savings from 2025 onwards and increase operational agility Appointment of seasoned industry executive Axel Malkomes as new CFO effective November 11, enhancing financial leadership and strategic execution CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m. |
accesswire.com |
2024-11-12 09:20:00 |
Czytaj oryginał (ang.) |
| CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 |
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. |
accesswire.com |
2024-11-07 09:30:00 |
Czytaj oryginał (ang.) |
| CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer |
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformation TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024. |
accesswire.com |
2024-11-04 09:20:00 |
Czytaj oryginał (ang.) |
| CureVac to Present at the 12th International mRNA Health Conference |
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024. |
accesswire.com |
2024-11-04 09:15:00 |
Czytaj oryginał (ang.) |
| CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting |
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 8-10 in Houston, USA. |
accesswire.com |
2024-10-28 10:10:00 |
Czytaj oryginał (ang.) |
| Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents |
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. |
reuters.com |
2024-10-08 09:50:43 |
Czytaj oryginał (ang.) |
| CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress |
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, observed in patients without pre-existing T-cell activity against encoded cancer antigens CVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicities Most common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection 100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollment TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 13, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today presented compelling data from the dose-escalation Part A of its ongoing Phase 1 CVGBM cancer vaccine study in patients with glioblastoma at the European Society for Medical Oncology (ESMO) Congress. |
accesswire.com |
2024-09-13 12:15:00 |
Czytaj oryginał (ang.) |
| CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program |
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that GSK has reported positive Phase 2 headline data from the seasonal influenza mRNA vaccine program. |
accesswire.com |
2024-09-12 11:15:00 |
Czytaj oryginał (ang.) |
| CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress |
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first clinical data from CureVac's ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be presented at the European Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September 13-17, 2024). |
accesswire.com |
2024-09-09 11:15:00 |
Czytaj oryginał (ang.) |
| CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update |
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platform Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areas Invoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreement Dosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMO Strengthening of Supervisory Board with appointment of innovation expert Birgit Hoffman and clinical oncologist Mehdi Shahidi, M.D. Chief Financial Officer, Pierre Kemula, to step down at the end of his term October 31, 2024; search for a replacement ongoing with transition plan in place Cash and cash equivalents position of €202.5 million as of June 30, 2024, not including €400 million upfront payment from GSK agreement; reaffirming cash runway into 2028 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. |
accesswire.com |
2024-08-15 11:30:00 |
Czytaj oryginał (ang.) |
| CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma |
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM Part B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma. |
accesswire.com |
2024-08-15 11:20:00 |
Czytaj oryginał (ang.) |
| CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board |
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today named clinical oncologist Mehdi Shahidi, M.D. |
accesswire.com |
2024-08-15 11:15:00 |
Czytaj oryginał (ang.) |
| CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy? |
CureVac (CVAC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-08-08 15:00:25 |
Czytaj oryginał (ang.) |
| CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock? |
CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-07-15 17:01:36 |
Czytaj oryginał (ang.) |
| CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech |
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 11, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany. |
accesswire.com |
2024-07-11 11:15:00 |
Czytaj oryginał (ang.) |
| Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer |
ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (Nasdaq: CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac's financial and capital markets activities since 2016, characterized by a successful listing on N. |
businesswire.com |
2024-07-11 11:00:00 |
Czytaj oryginał (ang.) |
| CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts |
CureVac (NASDAQ: CVAC ) layoffs are coming for the vaccine maker's employees as it prepares to undergo a restructuring to streamline its business. CureVac has announced that its layoffs will affect 30% of its global workforce. |
investorplace.com |
2024-07-03 15:49:34 |
Czytaj oryginał (ang.) |